On day 32 post-treatment, the T cell group (tumor size: 976 ± 437.3 mm3) and the anti-PSMA/anti-CD3 BsAb groups (Fab-scFv and scFv-Fab) (tumor sizes: 1004 ± 876.33 mm3 and 987 ± 654.4 mm3, respectively) were not effective in inhibiting tumor growth (control group, 878 ± 386.6 mm3). Here, FOLH1 is linked to neoplasm.